Anixa Biosciences, Inc.
Amit Kumar is a seasoned executive with extensive experience in the biotechnology sector and leadership roles across various organizations. Currently serving as Chairman and CEO of Anixa Biosciences, Inc., Amit oversees the development of innovative immunotherapies and cancer diagnostics. Additionally, as Chairman and Co-Founder of EdisonXFC, Amit is focused on expanding a network of fast charging stations for electric vehicles. Involvement with the American Cancer Society includes membership on the Regional Board of Directors, following a tenure on the National Board from 2017 to 2022. Previously, Amit held responsibilities as Executive Chairman and Co-Founder of Actym Therapeutics, led GFF as President and CEO, and rang as President and CEO of CombiMatrix Corporation, where a successful public offering occurred in 2002. Amit's educational credentials include a PhD in Physical Chemistry from Caltech and a Postdoctoral Fellowship at Harvard University.
This person is not in any teams
Anixa Biosciences, Inc.
Anixa Biosciences (NASDAQ:ANIX) is a clinical stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company’s vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer--specifically triple negative breast cancer (TNBC), the most lethal form of the disease--as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization.